MET and glioblastoma: In addition, TBMS I also increases the ubiquitination level of protooncogene (MET) to decrease the protein level of MET, thereby repressing the abnormal activation and amplification of MET, and ultimately inhibiting the proliferative activity of glioblastoma (Cao et al., 2019).